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Abstract. Advanced head and neck cancer (HNC) can invade 
facial bone and cause bone pain, thus posing a significant 
challenge to the quality of life of patients presenting with 
advanced HNC. The present study was designed to investigate 
HNC bone pain (HNC-BP) in an intratibial mouse xenograft 
model that utilized an HNC cell line (SAS cells). These mice 
develop HNC-BP that is associated with an expression of phos-
phorylated ERK1/2 (pERK1/2), which is a molecular indicator 
of neuron excitation in dorsal root ganglia (DRG) sensory 
neurons. Our experiments demonstrated that the inhibition of 
high mobility group box 1 (HMGB1) by short hairpin (shRNA) 
transduction, HMGB1 neutralizing antibody, and HMGB1 
receptor antagonist suppressed the HNC-BP and the pERK1/2 
expression in DRG. It was also observed that HNC-derived 
HMGB1 increased the expression of the acid-sensing noci-
ceptor, transient receptor potential vanilloid 1 (TRPV1), which 
is a major cause of osteoclastic HNC-BP in DRG. Collectively, 
our results demonstrated that HMGB1 originating in HNC 
evokes HNC-BP via direct HMGB1 signaling and hypersensi-
tization for the acid environment in sensory neurons.
Introduction
Head and neck cancer (HNC) frequently infiltrates and 
metastasizes bones (1), resulting in HNC-associated bone 
pain (HNC-BP) (2). Cancer pain is a prognostic factor of 
poor clinical outcomes (3). HNC-BP often reduces the ability 
to eat and swallow, thus posing a significant challenge to the 
quality of life of patients presenting with advanced HNC. The 
pathophysiology of bone pain associated with HNC is poorly 
understood (4), and HNC-BP is frequently inadequately treated.
Dead cells, dendritic cells, and cancer cells releases 
damage-associated molecular patterns (DAMPs), which initiate 
noninfectious inflammatory responses (5). Among the various 
DAMPs, high mobility group box 1 (HMGB1) was first discov-
ered as a conserved non-histone DNA-binding protein and has 
been the most intensively studied (6). A 2015 study revealed 
that HMGB1 mediates inflammatory and immune reactions 
in the nervous system (7), and emerging evidence indicates 
that HMGB1 plays an essential role in neuropathic pain (8). 
Extracellular HMGB1 activates the receptor for advanced 
glycation end products (RAGE) and Toll-like receptor 4 (TLR4), 
promoting pain signals (9,10). It was revealed that HMGB1 
is overexpressed in the serum and tissues in several types of 
cancer, including breast cancer, malignant mesothelioma, and 
other malignancies (11,12). However, the role of cancer-derived 
HMGB1 in HNC-BP remains unknown.
Cancer cells in bone metastasis and at bone invasion sites 
secrete significant amounts of growth factors, promoting osteo-
clastogenesis (13,14). The best-known molecular pain inducer 
in HNC-BP is osteoclast-derived proton (H+) (15). In the cancer 
bone microenvironment, cancer cells and osteoclasts secrete 
protons through the proton pump, creating an acidic microen-
vironment in the bone marrow (16). This environment activates 
pH-sensitive sensory neurons via acid-sensing nociceptors such 
as transient receptor potential vanilloid 1 (TRPV1), eliciting 
bone pain (17). The findings of the present study provide initial 
evidence that HNC-derived HMGB1 directly activates sensory 
neurons and increases the expression of TRPV1, thus indirectly 
promoting acid-induced HNC-BP.
Materials and methods
Reagents. Puromycin dihydrochloride (#P9620) was purchased 
from Sigma-Aldrich; Merck KGaA. TLR4 antagonist TAK-242 
(#13871) and RAGE antagonist FPS-ZM1 (#11909) were 
purchased from Cayman Chemical Co. Chicken anti-HMGB1 
High mobility group box 1 induces bone pain associated with bone 
invasion in a mouse model of advanced head and neck cancer
TOMOYA NAKAMURA1,  TATSUO OKUI1,  KAZUAKI HASEGAWA1,  
SHOJI RYUMON1,  SOICHIRO IBARAGI1,  KISHO ONO1,  YUKI KUNISADA1,  
KYOICHI OBATA1,  MASANORI MASUI1,  TSUYOSHI SHIMO2  and  AKIRA SASAKI1
1Department of Oral and Maxillofacial Surgery and Biopathology, Okayama University Graduate School of Medicine,  
Dentistry and Pharmaceutical Science, Okayama 700-8525; 2Division of Reconstructive Surgery for Oral and Maxillofacial Region, 
Department of Human Biology and Pathophysiology, School of Dentistry, 
Health Sciences University of Hokkaido, Hokkaido 061-0293, Japan
Received July 16, 2020;  Accepted September 11, 2020
DOI: 10.3892/or.2020.7788
Correspondence to: Dr Tatsuo Okui, Department of Oral and 
Maxillofacial Surgery and Biopathology, Okayama University 
Graduate School of Medicine, Dentistry and Pharmaceutical 
Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama 700-8525, Japan
E-mail: pphz1rke@okayama-u.ac.jp
Key words: head and neck cancer, bone pain, HMGB1, RAGE, 
sensory neuron
NAKAMURA et al:  HMGB1 INDUCES BONE PAIN IN ADVANCED HNC2548
polyclonal antibody (#326052233) was purchased from 
Shino-Test. Control shRNA plasmid-A (#sc-108060), HMG-1 
shRNA plasmid (#sc-37982-SH), and anti-RAGE antibody 
(anti-mouse, monoclonal, sc-80652) were purchased from 
Santa Cruz Biotechnology, Inc. HMGB1 antibody (anti-mouse, 
monoclonal, GTX628834) was purchased from GeneTex, Inc. 
Anti-phospho-p44/42 MAPK antibody (p-ERK; anti-rabbit, 
monoclonal, #4370), anti-p44/42 MAPK antibody (ERK; 
anti-rabbit, monoclonal, #4695), horseradish peroxidase 
(HRP)-conjugated IgG antibody (goat anti-rabbit, monoclonal, 
#7074), HRP-conjugated IgG antibody (goat anti-mouse, mono-
clonal, #7076), and Alexa Fluor 488-conjugated IgG (H+L) 
F(ab')2 fragment (goat anti-rabbit, monoclonal, #4412) were 
purchased from Cell Signaling Technology, Inc. Anti-TLR4 
antibody (anti-rabbit, polyclonal, #ab13556), anti-β-actin 
antibody (anti-mouse, monoclonal, #ab49900), anti-CGRP 
antibody (anti-goat, polyclonal, #ab36001), and Alexa Fluor 
647-conjugated IgG H&L antibody (donkey anti-goat, mono-
clonal, #ab150135) were purchased from Abcam.
Cell lines and culture conditions. The human HNC cell 
lines SAS (#JCRB0260), HSC-2 (#JCRB0622), HSC-3 
(#JCRB0623), HSC-4 (#JCRB0624), OSC-19 (#JCRB0198), 
and mouse fibroblast cell line 3T6 (#JCRB9059) were obtained 
from the Human Science Resources Bank (Osaka, Japan). All 
of these cell lines were cultured in Dulbecco's modified Eagle's 
medium (DMEM) (Thermo Fisher Scientific, Inc.) supple-
mented with 10% heat-inactivated fetal bovine serum (FBS) 
and 1% penicillin-streptomycin. The rat DRG neuronal cell 
line 50B11 was kindly provided by Dr A. Hoke (Department 
of Neurology, School of Medicine, Johns Hopkins University, 
Baltimore, MD, USA) and cultured in neurobasal medium. 
MLO-A5 cells provided by Dr T. Bellido (Department of 
Anatomy and Cell Biology, School of Medicine, Indiana 
University, Indianapolis, IN, USA) and primary mouse 
osteoblast cells (OBC12) (Cosmo Bio, Tokyo) were cultured 
in α-MEM (minimal essential medium) containing 5% FBS. 
Cells of the mouse macrophage cell line RAW264.7 were 
cultured in α-MEM containing 10% FBS.
Rat DRG cells were obtained from Lonza Japan and 
cultured according to the supplier's instructions. All cell lines 
were cultured in an atmosphere of 5% CO2 at 37˚C.
Immunohistochemical analysis. We analyzed the expression 
of HMGB1 in HNC tissue and a normal tissue microarray 
(#OR601d; US Biomax). The antigen was activated by cooking 
in a citric acid solution. For the immunohistochemical 
analysis, the specimens were incubated with anti-HMGB1 
antibody (dilution 1:200) overnight at 4˚C. The slides were 
then treated with a streptavidin-biotin complex (EnVision 
System labeled polymer, HRP; Dako; Agilent Technologies, 
Inc.) for 60 min at a dilution of 1:100. The immunoreaction 
was visualized with the use of a DAB substrate-chromogen 
solution (Dako Cytomation Liquid DAB Substrate Chromogen 
System, Agilent Technologies, Inc.). The cells were counted 
using a light microscope and evaluated.
Analysis of HMGB1 expression in SAS cells. SAS cells 
were transfected with 5.0 µg control short hairpin (sh)RNA 
or HMGB1 shRNA with the use of 4D-Nucleofector™ 
(Lonza Group, Ltd.). Two days later, the cells were cultured 
in DMEM + 10% FBS for 5 days in the presence of 1.6 µg/ml 
puromycin dihydrochloride for the selection of cells that stably 
expressed the shRNAs.
The hairpin sequence was as follows: GAT CCA AGC ACC 
CAG ATG CTT CAG TTT CAA GAG AAC TGA AGC ATC TGG 
GTG CTT TTT TT. The corresponding siRNA sequences were 
sense, AAG CAC CCA GAU GCU UCA GUtt and antisense, 
ACU GAA GCA UCU GGG UGC UUtt. All sequences are 
provided in 5'→3' orientation.
Cell proliferation assay. SAS cells were plated in 24-well 
plates at 1.5x104 cells per well. Their number was counted 
72 h later with a TC20 automated cell counter according to 
the manufacturer's instructions (Bio-Rad Laboratories, Inc.).
Western blot analysis. The cell lysates were mixed with 4X 
Laemmli sample buffer (Bio-Rad Laboratories, Inc.) and 
heated at 95˚C for 5 min. The samples were electrophoresed 
on 4-12% SDS-PAGE gels, and the proteins were transferred 
onto PVDF membranes (Bio-Rad Laboratories, Inc.). The 
membranes were incubated with primary and secondary 
antibodies according to the ECL chemiluminescence protocol 
(RPN2109; Amersham Biosciences) to detect secondary anti-
body binding. Antibodies against HMGB1 (1:1,000), TLR-4 
(1:500), RAGE (1:1,000), p-ERK (1:1,000), ERK (1:1,000), 
TRPV1 (1:1,000), and β-actin (1:10,000) were used as the 
primary antibodies. HRP-conjugated anti-rabbit antibody 
(1:2,000) and HRP-conjugated anti-mouse antibody (1:2,000) 
were used as the secondary antibodies.
We evaluated the effects of three redox forms of HMGB1 on 
sensory neuronal excitation. Cells of the DRG neuronal cell line 
50B11 were cultured on 6-well plates (5x104/well) in DMEM 
and incubated for 24 h after the addition of each isoform of 
HMGB1 (HMGB1 Isoform Kit, #HM-030, HMGBiotech). The 
protein was then collected. A ChemiDoc MP system (Bio-Rad 
Laboratories, Inc.) was used for the analysis of the western blots.
Sensory neuron fiber sprouting assay. DRG cells were plated 
on 48-well plates (1x104/well) in neuron growth medium 
for 24 h. The conditioned medium of SAS, short hairpin 
(sh)-control SAS, and sh-HMGB1 SAS cells was added to 
each well at 30% of the total medium volume. The conditioned 
medium had been collected after the incubation of 5.0x106 of 
each cell in DMEM plus 2% FBS for 24 h.
We also evaluated an HMGB1 neutralizing antibody which 
was applied to the wells with conditioned medium of SAS at the 
following concentrations: Anti-HMGB1 polyclonal antibody 
(100 ng/ml). DRG fibers were visualized by calcein acetoxy-
methyl (AM) staining on Day 5. DRG neuronal fibers were 
observed with a Keyence microscope (magnification, x200) 
(BZ-8100; Osaka, Japan).
Animal experiments. We established a mouse model of bone 
invasion by human HNC in 7-week-old male BALB/c nude 
mice (each group, n=8; total, n=56; mean body weight, 24.3 g; 
Charles River Laboratories, Yokohama, Japan) by the inocula-
tion of 1x105 SAS cells (parental, sh-control, sh-HMGB1) with 
a 29-gauge needle into the bone marrow space of the right 
tibial edge of the mouse under anesthesia with 0.4 mg/kg of 
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medetomidine, 4.0 mg/kg of midazolam, and 5.0 mg/kg of 
butorphanol. The sham procedure was only a puncture with 
a 29-gauage needle into the right tibial cavity. Body condition 
scoring was applied and body weight was monitored daily. 
Mice were maintained in housing conditions at a temperature 
of 23±1˚C, humidity of 40‑80% and lighting time of 12 h from 
8 am to 8 pm. Food and water were taken freely.
Mechanical hyperalgesia was evaluated every other day on 
postoperative day (POD)1-9 in each group of mice. We also 
evaluated the effects of the HMGB1 neutralizing antibody and 
receptor antagonist. SAS-inoculated mice were treated with 
intraperitoneal injections of anti-HMGB1 polyclonal antibody, 
RAGE antagonist FPS-ZM1, and TLR4 antagonist TAK-242 
on POD10, and then we performed the assay every 6 h over a 
24-h period. The mice were individually placed in a cage with a 
mesh floor, over a moveable pressure‑stimulating filament. The 
filament was positioned under the center of the hind paw, and 
the time (sec) from stimulus onset to withdrawal was recorded. 
Previously we reported that SAS tumor progression in the tibia 
promotes bone destruction and fracture around POD20 (18). 
In this research we evaluated the direct cancer bone pain 
before fracture. On POD10, the mice underwent cardiac blood 
collection under anesthesia with 0.4 mg/kg of medetomidine, 
4.0 mg/kg of midazolam and 5.0 mg/kg of butorphanol (i.p), 
followed by cervical dislocation. Ipsilateral L4-L5 DRGs and 
the right tibia were then harvested. The criteria of humane 
endpoints for euthanasia was loss of >20 percent of body 
weight compared to the age-matched controls. Death of the 
animal was verified by cessation of cardiovascular and respi-
ratory movements. All of the animal experimental protocols 
were approved by the Ethics Review Committee for Animal 
Experimentation of the Okayama University Graduate School 
of Medicine and Dentistry (OKU-2018701, 20/Nov/2018).
In vivo analysis of HNC‑BP. We evaluated the mechanical 
hyperalgesia in the mice with the use of a Dynamic Plantar 
Aesthesiometer (#37450; Ugo Basile), which measures an 
animal's withdrawal latency to non-painful pressure at the 
proximal half of the plantar surface of the ipsilateral hind paw, 
and we applied an increasing force (2.75 g/sec). Prior to this 
examination, the mice were allowed to acclimate to the testing 
environment for 30 min. The testing environment consisted of 
translucent plastic-walled individual chambers with a metal 
mesh bottom. When the mouse withdrew its hind paw, the 
mechanical stimulus stopped automatically and the latency 
was recorded by the device precisely in 0.1-sec increments. The 
test was performed every other day on POD1-9 in the sham, 
parental, sh-control and sh-HMGB1 groups. For the evalua-
tions of the effects of the HMGB1 neutralizing antibody and 
receptor antagonist, intraperitoneal injections of anti-HMGB1 
antibody (2 mg/kg), FPS-ZM1 (10 mg/kg), and TAK-242 
(10 mg/kg) were respectively conducted for SAS-inoculated 
mice, and the assays were performed every 6 h over the 24-h 
period on POD10. The concentration of agents used in vivo are 
referenced from previous studies (19-21).
In vivo radiography and the measurement of osteolytic 
lesion areas. Osteolytic bone destruction was assessed on 
radiographs. The bones were placed against films (22x27 cm; 
Fuji Industrial Film FR; Fuji Photo Film) and exposed to soft 
X-rays at 35 kV for 15 sec with the use of a Sofron apparatus 
(Sofron).
HMGB1 concentration measurement. The HMGB1 concentra-
tions in the mouse tibia, whole blood serum, and conditioned 
medium were evaluated by enzyme-linked immunosorbent 
assay (ELISA). Both ends of the tibias were cut, and the bone 
marrow serum was extracted by centrifugation. The culture 
supernatant had been collected after the incubation of 5.0x106 
parental, sh-control and sh-HMGB1 SAS cells in DMEM 
plus 2% FBS for 24 h. Each concentration of HMGB1 was 
measured by the HMGB1 ELISA Kit (HMGB1 ELISA Kit II; 
Shino-Test). The protocol of the manufacturer was followed.
DRG processing. Corrected DRGs were homogenized in RIPA 
lysis buffer with 1 mM PMSF and phosphatase inhibitor (Na3VO4 
and NaF) added. The lysate was centrifuged at 15,000 x g for 
5 min at 4˚C, and the supernatant was collected as total protein. 
Some of the collected DRGs were fixed in 10% neutral‑buffered 
formalin and then embedded in paraffin. Western blotting and 
immunofluorescence were performed using these DRGs.
Immunofluorescence analysis. We conducted an immunofluo-
rescence analysis to determine the expressions of p-ERK in 
DRGs from each group of mice. The specimens were incu-
bated with 3% bovine serum albumin-phosphate buffered 
saline (BSA-PBS) blocking solution, and then with p-ERK 
antibody (dilution 1:200) and anti-CGRP antibody (dilution 
1:200) overnight at 4˚C as primary antibodies, followed by 
Alexa Fluor 488 anti-rabbit IgG (dilution 1:1,000) or and Alexa 
Fluor 647 anti-goat IgG (1:1,000) as secondary antibodies. 
Nuclei were counterstained with Fluoroshield mounting 
medium with DAPI (#ab104139; Abcam).
Statistical analyses. The data were analyzed using an unpaired 
Student's t-test for comparisons of two groups and by performing 
a one-way analysis of variance (ANOVA) and a post hoc Tukey's 
test for the analysis of multiple group comparisons with Graph 
Pad Prism, ver. 7.0 (GraphPad Software, Inc.). The results are 
expressed as the mean ± standard deviation (SD). Probability 
(P)‑values <0.05 were considered significant.
Results
HMGB1 expression in the human HNC samples. Fig. 1 
provides a representative histologic pattern of normal oral 
tissue and HNC tissue. HMGB1 was highly expressed in the 
HNC patient samples compared to the normal head and neck 
samples (Fig. 1A and B). The ratios of HMGB1-positive nuclei 
in each HNC sample and the normal oral tissues were the 
same, but the ratio of cytoplasm HMGB1-positive cells was 
much higher in the HNC tissue compared to the normal oral 
tissue (Fig. 1C).
Effect of HNC‑derived HMGB1 on neurite sprouting. To 
determine whether HNC cells express HMGB1 in vitro, we 
performed a western blot analysis of HMGB1 expression in 
the HNC cell lines. As shown in Fig. 2A, the results of the 
western blot analysis revealed high expression of HMGB1 in 
the SAS cells. To examine the role of cancer-derived HMGB1 
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in neurite sprouting in vitro, we first evaluated the expression 
of HMGB1 in sensory neurons. Fig. 2B demonstrates that 
the bone and neuronal cell lines expressed both RAGE and 
TLR4.
We next cultured the DRG sensory neuron cells in neuron 
growth medium containing conditioned medium of SAS (CM) 
with or without HMGB1 neutralizing antibody (Ab) to evaluate 
sensory neuron axis sprouting. Fig. 2C and D shows that the 
cultures with SAS CM exhibited increased neuron lengths, 
and the HMGB1 neutralizing antibody suppressed that effect.
HMGB1 neutralizing antibody suppresses HNC‑BP and 
sensory nerve excitation in vivo. The mouse tibias injected 
with SAS cells developed aggressive proliferation of SAS cells 
in the bone marrow and bone destruction (Fig. 3A). To evaluate 
the role of HMGB1 in SAS-induced HNC-BP, we investigated 
SAS injection-induced mechanical hyperalgesia in the mouse 
bone marrow after the injection of SAS cells. At POD10, we 
observed that the treatment with the HMGB1 neutralizing 
antibody significantly reduced hyperalgesia compared to the 
parental SAS cell-injected mice (Fig. 3B).
In parallel with the HNC-BP results, the DRGs from the 
SAS-injected mice demonstrated an increased expression of 
phosphorylated (p)-ERK1/2, which is a molecular indicator of 
neuron excitation. In contrast, the DRGs from the sham-oper-
ated mice and the HMGB1 neutralizing antibody-treated mice 
showed decreased p-ERK1/2 expression in the western blot 
analysis (Fig. 3C).
RAGE and the TLR4 antagonist suppress the sensory nerve 
excitation and HNC‑BP in vivo. To evaluate the role of the 
HMGB1 receptor in SAS-induced HNC-BP, we investigated 
SAS injection-induced mechanical hyperalgesia. Treatment 
with the RAGE antagonist FPS-ZM1 or TLR4 antagonist 
TAK‑242 both significantly reduced hyperalgesia compared to 
the SAS cell-injected mice (Fig. 4A). As expected, the DRGs 
from the mice administered the RAGE antagonist or TLR4 
antagonist showed significantly decreased p‑ERK1/2 expres-
sion in the western blot and immunofluorescence analyses 
(Fig. 4B and C). Calcitonin gene-related peptides (CGRP) are 
neuropeptides expressed in sensory nerve, and are a positive 
control of sensory neurons.
Reduction in HMGB1 in SAS cells decreases sensory nerve 
sprouting. Next, to investigate the role of cancer-derived 
HMGB1 in HNC-BP, we introduced an shRNA plasmid 
targeting HMGB1 into SAS cells by an electroporation system. 
As shown in Fig. 5A, a 60% suppression of the expression of 
HMGB1 protein in SAS was observed in the shHMGB1-trans-
fected group (sh-HMGB1) compared to the parental SAS cells 
and control shRNA (sh-control) plasmid-introduced group. 
The proliferation ability of the HMGB1-knockdown SAS cells 
did not differ significantly from that of the sh‑control SAS 
cells (Fig. 5B). HMGB1 in conditioned medium tended to be 
decreased in the shHMGB1-transfected SAS cells (Fig. 5C). 
This conditioned medium promoted significantly less sensory 
neuron sprouting in the in vitro cultures (Fig. 5D and E).
HMGB1 derived from HNC promotes HNC‑BP and the exci‑
tation of sensory nerves in vivo. To evaluate cancer-derived 
HMGB1, we injected the parental, sh-control, and sh-HMGB1 
SAS cells into mouse tibial bone marrow and determined 
the systemic and local serum HMGB1 concentrations on 
POD10. Tumor area of the SAS parental (Fig. 6A-a), sh-control 
(Fig. 6A-b) and sh-HMGB1 (Fig. 6A-c) cell groups are shown. 
At a point on POD10, there were no significant differences in 
regards to tumor burden in the tibia and body weight between 
the HMGB1-knockdown SAS vs. parental and sh-control SAS 
cell‑injected mice (Fig. 6A‑d and ‑e). There were no significant 
between-group differences in the HMGB1 concentrations in the 
cardiac tissues (Fig. 6B-a). Compared to the parental SAS and 
sh-control SAS cell-injected mice, the injection of sh-HMGB1 
SAS cells significantly decreased the HMGB1 levels in the 
bone marrow (Fig. 6B-b). In parallel with these results, HMGB1 
knockdown significantly reduced hyperalgesia compared to the 
parental SAS- and sh-control SAS cell-injected mice on POD5, 
7 and 9 (Fig. 6C). Similar to the HNC-BP results, the DRGs 
Figure 1. Expression of HMGB1 in HNC and head and neck normal tissues. 
(A) Immunohistochemistry analysis of HMGB1 in head and neck normal 
tissue (a) and HNC tissue (b). Scale bar, 1 mm. (B) Scatterplot of the 
HMGB1-positive areas in the head and neck normal tissues (n=11) and HNC 
(n=70). Error bars: Mean ± SD. There was a significantly increased expres-
sion of HMGB1 in the HNC samples (*P<0.01). (C) The ratio of nucleic or 
cytoplasmic HMGB1-positive cells in the normal tissues and HNC tissues. 
Scale bar, 50 µm. Error bars: Mean ± SD. There was a significantly increased 
expression of HMGB1 in the cytoplasm of the HNC samples. *P<0.01. 
HMGB1, high mobility group box 1; HNC, head and neck cancer.
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from the parental SAS or sh-control SAS cell-injected mice 
demonstrated an increased expression of p-ERK1/2, which 
is a molecular indicator of neuron excitation. In contrast, the 
DRGs from the HMGB1-knockdown SAS cell-injected mice 
showed decreased p-ERK1/2 expression in the western blot and 
immunofluorescence analyses (Fig. 6D and E).
Figure 2. Effects of HMGB1 on neurite induction and outgrowth. (A) Expression of HMGB1 in HNC cell lines (HSC-2, HSC-3, HSC-4, SAS, OSC-19) and 
mouse fibroblast cell line (3T6) by western blot analysis. The right panel shows the quantification (n=3). (B) Expressions of RAGE and TLR4 in each cell 
line: Osteocytes (MLO-A5), osteoblasts (OBC12), macrophages prior to osteoclast differentiation (RAW264.7), and neurons (50B11). The right panel shows 
the quantification (n=3). (C) Neurite outgrowth from primary sensory neuron cells in neuron growth medium containing conditioned medium of SAS (CM) 
with/without HMGB1 neutralizing antibody. (a) Control, (b) SAS CM, and (c) SAS CM with HMGB1 antibody (Ab) for 5 days, labeled with calcein AM. Scale 
bar, 100 µm. (D) Quantitative data of neurite length shown in C. Error bars: Mean ± SD; *P<0.01 vs. SAS CM. HMGB1, high mobility group box 1; HNC, head 
and neck cancer; RAGE, advanced glycation end products; TLR4, Toll-like receptor 4.
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The three redox forms of HMGB1 have different roles in 
sensory neuron excitation. HMGB1 contains three conserved 
cysteine residues: Cys23, Cys45 and Cys106. The functions 
of HMGB1 depend on redox-sensitive cysteine residues 
(Cys23, Cys45 and Cys106) of the protein. HMGB1 has at 
least three redox forms with different biological functions: 
i) All-thiol HMGB1 (all three cysteine residues in the thiol 
state), ii) ‘disulfide HMGB1’ (an intramolecular disulfide 
bridge between Cys23 and Cys45; Cys106 in the thiol 
state), and ii) ‘Terminal oxidized HMGB1’ (all three cyste-
ines in the hyperoxidized sulfonic acid state). The western 
blot results indicated that all‑thiol HMGB1 and disulfide 
HMGB1 directly stimulated DRG sensory neuron cells as 
determined by a significant increase in p‑ERK. Furthermore, 
Figure 3. Contributions of HMGB1 to HNC-BP and sensory nerve excitation in vivo. (A) X-ray showing bone resorption of SAS cell-injected mouse tibia on 
POD10. (a) X-ray image of sham operated mouse, (b) X-ray image of SAS cell-injected mouse and (c) SAS cells colonization in bone marrow (hematoxylin 
and eosin staining). Scale bar, 1 mm. (B) Mechanical hyperalgesia of SAS-injected mice compared to the mouse group treated with HMGB1 neutralizing anti-
body (Ab) (2 mg/kg). The test was performed over the 24-h time course analysis POD10 (n=8). Error bars: Mean ± SD. *P<0.01 vs. SAS group. (C) Excitation 
of sensory nerves determined by phosphorylated (p)-ERK1/2 expression in dorsal root ganglia (DRG) by western blot analysis. (a) Representative blot and 
(b) quantification with densitometry of p‑ERK/ERK (n=3). Error bars: Mean ± SD. *P<0.05 vs. SAS group. HMGB1, high mobility group box 1; HNC, head 
and neck cancer; HNC-BP, HNC-associated bone pain; POD, postoperative day.
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they both sensitized the acid‑induced stimulation by signifi-
cantly increasing the TRPV1 expression, and also HMGB1 
neutralizing antibody addition suppressed TRPV1 expres-
sion (Fig. 7A and B).
Discussion
Bone-invasive cancer including head and neck cancer (HNC), 
breast cancer, and multiple myeloma frequently invade 
Figure 4. Effects of the HMGB1 receptor antagonists in HNC-BP in vivo. (A) The 24-h time course analysis of mechanical hyperalgesia following treatment 
with vehicle (0.1% DMSO in PBS), RAGE antagonist FPS-ZM1, or TLR4 antagonist TAK-242 (both 10 mg/kg) in SAS-injected mice on POD10 (n=8). Error 
bars: Mean ± SD. *P<0.05 vs. the SAS group. (B) Expression of phosphorylated (p-)ERK1/2 in the dorsal root ganglia (DRG) of the mice shown in panel A 
by western blot analysis. (a) Representative blot and (b) quantification with densitometry of p‑ERK/ERK (n=3). Error bars: Mean ± SD. *P<0.05 vs. the SAS 
group. (C) Immunofluorescence analysis of DRGs. Upper panels, p‑ERK1/2 (green); middle panels, CGRP (red); lower panels, merged. Scale bar, 50 µm. 
HMGB1, high mobility group box 1; HNC, head and neck cancer; HNC-BP, HNC-associated bone pain; CGRP, calcitonin gene-related peptide.
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and metastasize to bone, promoting bone pain. Cancer 
cells in bone marrow release various cytokines and growth 
factors (13), and these cytokines contribute to the activation 
of sensory neurons, leading to cancer-induced bone pain (22). 
Figure 5. Effect of the reduction in HMGB1 protein in the HNC SAS cells. (A) Expression of HMGB1 in the SAS cells. SAS cells stably transfected with control 
shRNA (sh-control) and HMGB1 shRNA (sh-HMGB1) and non-transfected cells (parental) were analyzed by western blot analysis for HMGB1 expression. 
The right panel shows their quantification (n=3). Error bars: Mean ± SD. *P<0.05 vs. sh-control. (B) Proliferation assay. Parental, sh-control, and sh-HMGB1 
cells were cultured for 72 h, and then the number of cells was counted (n=3). There was no significant difference between the cells in regards to proliferation 
ability. Error bars: Mean ± SD. (C) HMGB1 concentrations in the conditioned medium of each SAS group were determined by ELISA analysis (n=3). There 
was no significant different between the sh‑control and sh‑HMGB1, but a decline in HMGB1 in culture supernatants was observed in sh‑HMGB1 compared 
to sh-control (P=0.067). (D) Neurite sprouting from DRG sensory neuron cells cultured with the conditioned medium of each group of SAS: (a) control (b) 
parental CM (c) sh-control CM (d) sh-HMGB1 CM for 5 days, labeled with calcein AM. Scale bar, 100 µm. (E) Quantitative data of neurite length shown in D. 
Error bars: Mean ± SD; *P<0.01 vs. sh-control CM. HMGB1, high mobility group box 1; HNC, head and neck cancer.
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High mobility group box 1 (HMGB1) is a 25-kDa non-histone 
DNA binding protein that is generally distributed in the cell 
nucleus. The best-studied roles of HMGB1 are those in the 
immune system. Nuclear HMGB1 acts as a DNA chaperone 
Figure 6. Effect of the reduction of HMGB1 on HNC-BP and sensory neuron excitation in vivo. (A) Tumor area of SAS parental, sh-control and sh-HMGB1 groups 
in tibia bone marrow (hematoxylin and eosin) at x40 magnification. Scale bar, 1 mm. (a) Parental, (b) sh‑control and (c) sh‑HMGB1 groups. (d) Quantitative 
data (n=4). There was no significant difference between each of them. (e) Body weight of each group on POD10 (n=8). (B) HMGB1 concentrations in cardiac 
blood samples and tibia bone marrow. (a) HMGB1 concentration in the cardiac blood (n=3). (b) HMGB1 concentration in the tibia bone marrow (n=4). Error 
bars: Mean ± SD. *P<0.01 vs. sh-control. (C) Mechanical hyperalgesia results of each group. The test was performed every other day from POD1 to POD9 
(n=8). Error bars: Mean ± SD. *P<0.05 vs. sh-control. (D) Excitation of sensory neurons determined by phosphorylated (p-)ERK1/2 expression in the DRGs of 
the sham, parental, sh‑control, sh‑HMGB1 SAS‑injected mice by western blotting analysis. (a) Representative blot and (b) quantification with densitometry of 
p-ERK/ERK (n=3). Error bars: Mean ± SD. *P<0.05 vs. sh‑control. (E) Immunofluorescence analysis of DRGs. Upper panels, p‑ERK1/2 (green); middle panels, 
CGRP (red); lower image, merged. Scale bar, 50 µm. HMGB1, high mobility group box 1; HNC, head and neck cancer; HNC-BP, HNC-associated bone pain; 
POD, postoperative day; CGRP, calcitonin gene-related peptide.
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which regulates DNA repair and transcription (23). HMGB1 
is also a damage-associated molecular pattern (DAMP), that is 
released from dead cells and dendritic cells (24,25). HMGB1 is 
considered an inflammatory cytokine released from activated 
monocytes and macrophages (26,27).
It has been reported that HMGB1 secreted from various 
cancer cells and the blood serum HMGB1 concentration are 
both correlated with poor patient prognosis (28,29). Another 
study indicated that HMGB1 promotes sensory neuron 
sprouting and neuropathic pain in diseases such as pancreatitis, 
bladder pain, and arthritis (30). However, the role of HMGB1 
in HNC bone pain (HNC-BP) remains unclear. Our present 
findings demonstrated that HNC SAS cells express HMGB1 
in the cytoplasm and subsequently release HMGB1 to the 
extracellular space. In addition, our in vivo data revealed that 
HNC cells actively effuse HMGB1 to the extracellular space 
in bone marrow.
HMGB1 was found to evoke the influx of Ca in the neuron 
axis (31). Our present findings showed that SAS cells promote 
sensory neuron sprouting and elongation of the axis, and 
HMGB1 neutralizing antibody suppressed SAS conditioned 
medium-induced sensory neuron sprouting. These results 
indicate cancer-derived HMGB1 sensitization via increasing 
the length of sensory neuron axis.
Cytokines released from cancer promote osteoclastogen-
esis, and osteoclasts subsequently resorb the bone matrix by 
protons (32). The extracellular environment that is created by 
releasing protons from osteoclasts and by cancer contributes 
to the activation of sensory neurons and bone pain (15,33). 
Osteoclasts release protons via a3V-ATPase, which is a V-type 
proton pump (34). Cancer cells released protons as lactic acid 
in a metabolic process (35).
The phosphorylation of ERK and CREB is a marker of 
sensory neuron excitation. Our present results demonstrated 
that SAS cell-derived HMGB1 increased the acid sensitivity of 
sensory neuron cells via the HMGB1 axis. Calcium influx is a 
direct indicator of cell excitation. Herein, the HMGB1 neutral-
izing antibody and RAGE antagonist similarly suppressed 
the cell excitation by proton stimulation followed by SAS 
conditioned medium co-incubation. We therefore speculate 
that HMGB1 from cancer cells enhances HNC-BP via acid 
sensitization.
As expected, the HMGB1 neutralizing antibody suppressed 
the cancer bone pain that was caused by SAS cell injection into 
mouse tibial bone. HMGB1 is released from various cells such 
as dendritic cells and necrotic cells. To investigate the impor-
tance of cancer-derived HMGB1 for HNC-BP but not other 
microenvironmental cells, we established HMGB1-knockdown 
SAS cells. The results showed that the HMGB1 level in the 
bone marrow was correlated with the HMGB1 expression 
in SAS cells. In addition, the HMGB1 knockdown in SAS 
cells decreased the sensory neuron excitation in vitro, and it 
decreased the HNC-BP in mice in vivo. This result indicated 
that the cancer-derived HMGB1 promoted HNC-BP.
Figure 7. Relation of the redox status of HMGB1 in sensory neuron excitation. (A) Excitation of sensory neurons by different redux-statuses of HMGB1 as 
determined by phosphorylated (p‑)ERK1/2 expression. (a) Representative blot (b) and quantification with densitometry of p‑ERK/ERK (n=3). Error bars: 
Mean ± SD. *P<0.05 vs. control. (B) Expression of TRPV1 nociceptor in sensory neurons by different redux-status HMGB1 with/without HMGB1 neutralizing 
antibody (Ab). (a) Representative blot and (b) quantification (n=3). Error bars: Mean ± SD. *P<0.05 vs. disulfide, and vs. all‑thiol. TRPVI, transient receptor 
potential vanilloid 1; HMGB1, high mobility group box 1.
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HMGB1 has two receptors, i.e., TLR4 and RAGE (20). 
The question of which receptor(s) play a critical role in 
HNC-BP remains unanswered. It was reported that different 
redox states of the three cysteines of HMGB1 endow it with 
mutually exclusive activities (36). Fully reduced HMGB1 
binds mainly to RAGE, and disulfide HMGB1 binds to 
TLR4 (37). RAGE signaling is suspected to promote the 
phosphorylation of ERK, which is a marker of sensory 
neuron activation (38). The results of the present investi-
gation demonstrated that compared to the partly oxidized 
form (disulfide HMGB1), the fully reduced form (All‑thiol 
HMGB1) evoked sensory neuron excitation in vitro. In 
the in vivo experiment, the RAGE antagonist strongly 
suppressed HNC-BP compared to the TLR4 antagonist. Our 
results demonstrated that RAGE (and not TLR4) is critical 
for DRG excitation and HNC-BP.
In conclusion, our present findings demonstrated that 
the HMGB1 released from HNC cells promotes HNC bone 
pain via sensory neurons innervating bone marrow, acid 
sensing receptor TRPV1 activation, and a direct excita-
tion of sensory neurons by RAGE signaling rather than 
by a TLR4 pathway (Fig. 8). Targeting these pathways 
may provide effective mechanism-based therapies for 
the control of HNC-BP, which is currently undertreated. 
Furthermore, TLR4 and RAGE antagonist are expected as 
newly therapeutic agents against diabetes mellitus, sepsis 
and rheumatoid arthritis that are also painful diseases (39). 
Future research for HMGB1 will improve the treatment 
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